BIOMEVA and Boehringer Ingelheim strengthen their biomanufacturing services in a production alliance
The collaboration with Boehringer Ingelheim complements BIOMEVA GmbH´s current manufacturing capacities with large scale manufacturing capabilities allowing speed and flexibility, and securing high value for the customers.
Already one E.coli project regarding an antibody fragment has been transferred smoothly from Boehringer Ingelheim Austria GmbH to BIOMEVA GmbH. The process has been implemented successfully in a very short time and first GMP runs have been performed already five weeks after the first technology transfer meeting. Seven weeks later GMP material has been released for clinical trials.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.